Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 11:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Migraine, Headache, Multiple Sclerosis, Insomnia
Interventions: Smartphone-Based Progressive Muscle Relaxation Therapy (PMR), Monitored Usual Care (MUC); Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Stroke, Stroke, Acute, Stroke Hemorrhagic, Hemiparesis, Hemiplegia, Cerebrovascular Accident
Interventions: ReWalk ReStore device; Device
Lead sponsor: ReWalk Robotics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 5
States / cities: Chicago, Illinois • Boston, Massachusetts • West Orange, New Jersey + 2 more

Conditions: Cancer
Interventions: GSK1120212; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 7
States / cities: Los Angeles, California • Aurora, Colorado • New York, New York + 3 more

Conditions: Influenza, Pandemic Influenza
Interventions: H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen); Biological
Lead sponsor: Alachua Government Services, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 422 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: Wichita, Kansas • Lexington, Kentucky • Kansas City, Missouri + 3 more

Conditions: Chronic Insomnia
Interventions: Low Dose Drug A, Low Dose Drug B, High Dose Drug A, High Dose Drug B, SOM001-A, SOM001-B, SOM001-C, SOM001-D, Placebo; Drug
Lead sponsor: Somnum Pharma Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol 75 μg, Placebo to indacaterol; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 62
States / cities: Peoria, Arizona • Pine Bluff, Arkansas • Buena Park, California + 57 more

Conditions: Uterine Serous Carcinoma
Interventions: Adavosertib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 14
States / cities: Burbank, California • Duarte, California • La Jolla, California + 11 more

Conditions: Spinal Cord Injuries, Polytrauma, Burns
Interventions: placebo; Other
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Postoperative Pain
Interventions: Hydromorphone; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 28 Days to 16 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 14
States / cities: Little Rock, Arkansas • Orange, California • Stanford, California + 10 more

Conditions: Diabetic Foot, Ulcer Foot
Interventions: Human split thickness skin allograft, Additional Outer Dressing Applicaiton, Offloading, Fibracol Wound Dressing; Other
Lead sponsor: Professional Education and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: San Francisco, California • O'Fallon, Illinois • Youngstown, Ohio + 2 more

Conditions: Jaw, Edentulous, Partially
Interventions: Straumann Bone Level Implants, 4.1 mm implant diameter, Straumann Bone Level Implants, 3.3 mm implant diameter; Device
Lead sponsor: Institut Straumann AG; Industry
Eligibility: 20 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York + 2 more

Conditions: Circadian Rhythm Disorders
Interventions: LML134, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • Miami, Florida + 5 more

Conditions: Sickle Cell Disease, Thalassemia, Diamond-Blackfan Anemia
Interventions: Not listed
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 16 Years and older
Enrollment: 423 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 6
States / cities: Oakland, California • Augusta, Georgia • Chicago, Illinois + 3 more

Conditions: Chronic Inducible Urticaria
Interventions: Remibrutinib, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 25
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 21 more

Conditions: Malformations, Multiple Abnormalies, Polydactyly
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: Not listed
Enrollment: 1,170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2016
U.S. locations: 3
States / cities: Los Angeles, California • Bethesda, Maryland • Greenwood, South Carolina

Conditions: Progressive Supranuclear Palsy, Dementia With Lewy Bodies, Multiple System Atrophy, Corticobasal Syndrome, Atypical Parkinson Disease
Interventions: Home Visit Program, Usual Care/Online Survey; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 40 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Durvalumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Gainesville, Georgia • Knoxville, Tennessee

Conditions: Laxity; Skin
Interventions: MCD; Device
Lead sponsor: Cytrellis Biosystems, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Sacramento, California • Miami, Florida • New York, New York + 2 more

Conditions: Chronic Rhinitis, Inflammation of the Nasal Mucosa, Inflammation of Nasal Tissue
Interventions: Surgical turbinate reduction procedure; Procedure
Lead sponsor: ArthroCare Corporation; Other
Eligibility: 6 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 5
States / cities: San Diego, California • Aurora, Colorado • Boynton Beach, Florida + 2 more

Conditions: Lymphoma, Large B-Cell, Diffuse
Interventions: CC-122, CC-223, Rituximab, CC-292; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 8
States / cities: Stanford, California • New Haven, Connecticut • Tampa, Florida + 5 more

Conditions: Acquired Bleeding Disorder, Trauma
Interventions: activated recombinant human factor VII; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Plainsboro, New Jersey

Conditions: Osteoarthritis
Interventions: LNA043, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 23
States / cities: Phoenix, Arizona • Tucson, Arizona • La Mesa, California + 20 more

Conditions: Acne Vulgaris
Interventions: SB204 4%, Vehicle Gel; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 9 Years to 99 Years
Enrollment: 1,330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 55
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 50 more

Conditions: Chronic Nonmalignant Pain
Interventions: Buprenorphine transdermal patch; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 19
States / cities: Phoenix, Arizona • Trumbull, Connecticut • Clearwater, Florida + 16 more

Search by objective public record fields.

RELAXaHEAD for Headache Patients (Phase II)

Safety Evaluation of the ReWalk ReStore Device in Subjects With Mobility Impairments Due to Stroke

Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor

Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)

A Study of Oral SOM001 as a Safe and Effective Treatment for Adults With Chronic Insomnia in a Randomized, Controlled, Dose-finding Study

12-week Efficacy of Indacaterol

A Study of Adavosertib as Treatment for Uterine Serous Carcinoma

Conditioning & Open-Label Placebo (COLP) for Opioid Management in Intensive Inpatient Rehabilitation

An Open-label Study of Hydromorphone Oral Solution in Subjects Aged 28 Days to 16 Years for Postoperative Pain

Bioactive Split Thickness Skin Allograft Versus Standard of Care in the Treatment of Diabetic Foot Ulcers

Straumann Roxolid Multi-Center Study

A Study to Assess the Wakefulness Promoting Effect, Safety, Tolerability, and Pharmacokinetics (PK) of LML134 in Shift Work Disorder

Multi-Center Study of Iron Overload: Survey Study (MCSIO)

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

Phenotype and Etiology of Pallister-Hall Syndrome

In-Home Care for Patients With PSP and Related Disorders

A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Pivotal Study to Evaluate the Safety and Efficacy of a Micro-coring Device Treating Moderate to Severe Facial Wrinkles

Surgical Reduction of the Inferior Turbinates for Nasal Obstruction

Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury

Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis

P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne

Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study